Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LYN | P07948 | 2/20 | 0.54 |
| ▸ | TXK | P42681 | 2/20 | 0.54 |
| ▸ | SYK | P43405 | 2/20 | 0.54 |
| ▸ | AURKA | O14965 | 5/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.50 |
| ▸ | CDC7 | O00311 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | YES1 | P07947 | 1/20 | 0.46 |
| ▸ | FGR | P09769 | 1/20 | 0.46 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.46 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.46 |
| ▸ | EPHA3 | P29320 | 1/20 | 0.46 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.46 |
| ▸ | CSK | P41240 | 1/20 | 0.46 |
| ▸ | BLK | P51451 | 1/20 | 0.46 |
| ▸ | BMX | P51813 | 1/20 | 0.46 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.46 |
| ▸ | EPHA5 | P54756 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1131616 | 0.90 | AURKA (0.49) | LYNTXKSYKAURKAAURKB | |
| SCHEMBL1130949 | 0.88 | AURKA (0.51) | LYNTXKSYKAURKAAURKB | |
| SCHEMBL1131562 | 0.88 | SYK (0.49) | LYNTXKSYKAURKAAURKB | |
| SCHEMBL1131576 | 0.86 | AURKA (0.47) | LYNTXKSYKAURKAAURKB | |
| SCHEMBL1575673 | 0.84 | IGF1R (0.59) | AURKAAURKBCDC7EGFRLCK | |
| SCHEMBL1131032 | 0.82 | SYK (0.49) | LYNTXKSYKAURKAAURKB | |
| SCHEMBL1131143 | 0.80 | AURKA (0.47) | LYNTXKSYKAURKAAURKB | |
| SCHEMBL1575060 | 0.80 | IGF1R (0.58) | LYNTXKSYKAURKAEGFR | |
| SCHEMBL1131678 | 0.80 | IGF1R (0.55) | LYNTXKSYKAURKAAURKB | |
| SCHEMBL1131699 | 0.80 | EPHB4 (0.50) | LYNTXKSYKAURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283356-B2 | 2,4- Di(hetero)-arylamino-pyrimidine derivatives as ZAP-70 and/or SYK inhibitors | NOVARTIS AG (CH) | 2012-10-09 | — | — | US | claimed |
| EP-1664035-B1 | 2,4 DI(HETERO)-ARYLAMINO-PYRIMIDINE DERIVATIVES AS ZAP-70 AND/OR SYK INHIBITORS | NOVARTIS AG (CH) | 2011-02-16 | — | — | EP | claimed |
| EP-2266977-B1 | 2,4-di[(hetero)arylamino]-pyrimidine derivatives as zap-70 and/or syk inhibitors | NOVARTIS AG (CH) | 2014-05-14 | — | — | EP | disclosed |
| EP-2266977-B1 | 2,4-di[(hetero)arylamino]-pyrimidine derivatives as zap-70 and/or syk inhibitors | NOVARTIS AG (CH) | 2014-05-14 | — | — | EP | disclosed |
| US-8283356-B2 | 2,4- Di(hetero)-arylamino-pyrimidine derivatives as ZAP-70 and/or SYK inhibitors | NOVARTIS AG (CH) | 2012-10-09 | — | — | US | disclosed |
| US-8283356-B2 | 2,4- Di(hetero)-arylamino-pyrimidine derivatives as ZAP-70 and/or SYK inhibitors | NOVARTIS AG (CH) | 2012-10-09 | — | — | US | disclosed |
| US-8283356-B2 | 2,4- Di(hetero)-arylamino-pyrimidine derivatives as ZAP-70 and/or SYK inhibitors | NOVARTIS AG (CH) | 2012-10-09 | — | — | US | disclosed |
| EP-1664035-B1 | 2,4 DI(HETERO)-ARYLAMINO-PYRIMIDINE DERIVATIVES AS ZAP-70 AND/OR SYK INHIBITORS | NOVARTIS AG (CH) | 2011-02-16 | — | — | EP | disclosed |
| EP-2266977-A1 | 2,4-di[(hetero)arylamino]-pyrimidine derivatives as zap-70 and/or syk inhibitors | Novartis AG (CH) | 2010-12-29 | — | — | EP | disclosed |
| US-20100152182-A1 | 2,4- Di(hetero)-arylamino-pyrimidine Derivatives as ZAP-70 and/or SYK inhibitors | NOVARTIS AG (CH) | 2010-06-17 | — | — | US | disclosed |
| US-20100152182-A1 | 2,4- Di(hetero)-arylamino-pyrimidine Derivatives as ZAP-70 and/or SYK inhibitors | NOVARTIS AG (CH) | 2010-06-17 | — | — | US | disclosed |
| US-20100152182-A1 | 2,4- Di(hetero)-arylamino-pyrimidine Derivatives as ZAP-70 and/or SYK inhibitors | NOVARTIS AG (CH) | 2010-06-17 | — | — | US | disclosed |
| US-7671063-B2 | 2,4 Di (hetero) -arylamino-pyrimidine derivatives as ZAP-70 and/or syk inhibitors | NOVARTIS AG (CH) | 2010-03-02 | — | — | US | disclosed |
| US-7671063-B2 | 2,4 Di (hetero) -arylamino-pyrimidine derivatives as ZAP-70 and/or syk inhibitors | NOVARTIS AG (CH) | 2010-03-02 | — | — | US | disclosed |
| US-7671063-B2 | 2,4 Di (hetero) -arylamino-pyrimidine derivatives as ZAP-70 and/or syk inhibitors | NOVARTIS AG (CH) | 2010-03-02 | — | — | US | disclosed |
| US-20060247262-A1 | 2,4 Di (hetero) -arylamino-pyrimidine derivatives as ZAP-70 and/or syk inhibitors | NOVARTIS AG (CH) | 2006-11-02 | — | — | US | disclosed |
| EP-1664035-A1 | 2,4 DI (HETERO) -ARYLAMINO-PYRIMIDINE DERIVATIVES AS ZAP-70 AND/OR SYK INHIBITORS | Novartis AG (CH) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026158-A1 | 2,4 DI (HETERO) -ARYLAMINO-PYRIMIDINE DERIVATIVES AS ZAP-70 AND/OR SYK INHIBITORS | NOVARTIS AG (CH) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152182-A1 | 2,4- Di(hetero)-arylamino-pyrimidine Derivatives as ZAP-70 and/or SYK inhibitors | ZAP70, SYK, BTK | LYN 5/4885TXK 160/4885SYK 2/4885 |
| US-20060247262-A1 | 2,4 Di (hetero) -arylamino-pyrimidine derivatives as ZAP-70 and/or syk inhibitors | ZAP70, SYK, BTK | LYN 5/4885TXK 142/4885SYK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.